TABLE 1.
Mupirocin susceptibility and spa type changes of sequential isolates and genotypic resistance profile of 19 patients with persistent MRSA carriage after mupirocin nasal decolonizatione
| ID | Duration of MRSA carriage (yr) | Recorded no. of mupirocin courses |
Mupirocin susceptibility at: |
spa type at: |
Presence of antibiotic resistance gene in MRSA from persistent carrier at study end |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Prior to RCT | During RCT | Recruitment | RCT end | Recruitment | RCT end, 14 to 28 days later | mecA | blaZ | ileS2 | erm(C) | aphA3 | sat | tet(K) | qacA | ||
| 1114 | <1 | 2 | 2 | S | S | t7636 | t7636 | + | + | − | + | − | − | − | − |
| 1122a | <1 | 2 | 2 | S | HLMR | t4559 | t127 | + | + | + | + | + | + | + | + |
| 1126 | 3 | >2 | 2 | S | S | t4559 | t4559 | + | + | − | − | + | − | − | − |
| 1131 | <1 | >2 | 2 | S | S | t515 | t515 | + | + | − | + | + | − | − | − |
| 1136b | 9 | >2 | 2 | HLMR | HLMR | t032 | t032 | + | + | + | + | − | − | − | − |
| 1138 | 3 | >2 | 2 | S | S | t032 | t032 | + | + | − | − | − | − | − | − |
| 1141 | 4 | >2 | 2 | S | S | t032 | t032 | + | + | − | + | − | − | − | − |
| 1152 | 5 | 2 | 2 | S | S | t032 | t032 | + | + | − | + | − | − | − | − |
| 1153 | 12 | >2 | 2 | S | S | t515 | t515 | + | + | − | − | − | − | − | − |
| 1159 | 7 | >2 | 2 | S | S | t515 | t515 | + | + | − | − | − | − | − | − |
| 1163 | 4 | >2 | 2 | S | S | t032 | t032 | + | + | − | − | − | − | − | − |
| 1165 | <1 | >2 | 2 | S | S | t032 | t032 | + | + | − | − | − | − | − | − |
| 1180 | 6 | >2 | 2 | S | S | t032 | t032 | + | + | − | − | − | − | − | − |
| 1181 | <1 | 2 | 2 | S | S | t022 | t032 | + | + | − | + | − | − | − | − |
| 1184c | <1 | 2 | 2 | LLMR | HLMR | t1612 | t1612 | + | + | − | + | − | − | − | + |
| 1195a | <1 | 2 | 2 | S | HLMR | t127 | t127 | + | + | + | + | + | + | + | + |
| 1197b | 2 | 2 | 2 | HLMR | HLMR | t515 | t515 | + | + | − | + | − | − | − | − |
| 1208d | <1 | 2 | 2 | S | LLMR | t1612 | t1612 | + | + | − | + | − | − | − | − |
| 1210 | <1 | 2 | 2 | S | S | t032 | t032 | + | + | − | + | − | − | − | − |
Patient isolate developed HLMR (>1,024 mg/liter) following 2 courses of mupirocin.
Patient isolate was HLMR at start and end of study.
Patient isolate LLMR (8 to 256 mg/liter) at study start but HLMR following 2 courses of mupirocin.
Patient isolate developed LLMR following 2 courses of mupirocin.
RCT, randomized controlled trial; S, mupirocin susceptible; mecA, alternate penicillin binding protein 2; blaZ, beta-lactamase gene; ileS2, high-level mupirocin resistance gene; erm(C), gene encoding resistance to macrolides, lincosamides, and streptogramin B (MLSB) compounds; aphA3, gene encoding resistance to aminoglycosides; sat, streptothricin; tet(K), tetracycline; qacA, quaternary ammonium compound.